One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Personalizing tamoxifen therapy in adjuvant therapy: a brief summary of the ongoing discussion
Anabel Sanchez-Spitman & Henk-Jan Guchelaar
doi : 10.1080/17512433.2023.2154652
Expert Review of Clinical Pharmacology, Volume 16, Issue 2 (2023)
Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments
Georgios Polychronopoulos, Achilleas Papagiannis & Konstantinos Tziomalos
Aminoadamantanes: from treatment of Parkinson’s and Alzheimer’s disease to symptom amelioration of long COVID-19 syndrome?
Thomas Müller, Peter Riederer & Wilfried Kuhn
doi : 10.1080/17512433.2023.2176301
The aminoadamantanes amantadine and memantine are well known. They mainly act as N-methyl-D-aspartate antagonists.
Designer benzodiazepines: an update
Xiao Yu, H Karl Greenblatt & David J Greenblatt
doi : 10.1080/17512433.2023.2170349
Designer benzodiazepines (DBs) are a subclass of novel psychoactive substances (NPS). DBs mimic the properties of approved and prescribed benzodiazepines.
Shedding light on key pharmacological knowledge and strategies for pediatric atopic dermatitis
Ariana Moreno, Yael Renert-Yuval & Emma Guttman-Yassky
doi : 10.1080/17512433.2023.2173172
Atopic dermatitis (AD) is an inflammatory disease affecting over 20% of the pediatric population, with 85% of cases presenting before the age of five. Recently, therapeutic options in pediatric patients have evolved rapidly, following extensive development in adult treatments.
Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape
Antonio Solana-Altabella, Juan Eduardo Meg?as-Vericat, Octavio Ballesta- L?pez, David Mart?nez-Cuadr?n & Pau Montesinos
doi : 10.1080/17512433.2023.2174523
FLT3 inhibitors (FLT3i) are drugs in which there is limited experience and not yet enough information on the mechanisms of absorption, transport, and elimination; but especially on the potential drug-drug interactions (DDIs). There are therefore risks in the management of FLT3i DDIs (i.e. sorafenib, ponatinib, crenolanib, midostaurin, quizartinib, and gilteritinib) and ignoring them can compromise therapeutic success in acute myeloid leukemia (AML) treatment, in complex patients and secondary pathologies.
Clinical pharmacology of SGLT-2 inhibitors in heart failure
Maria Velliou, Effie Polyzogopoulou, Ioannis Ventoulis & John Parissis
doi : 10.1080/17512433.2023.2173574
Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute a class of oral antiglycemic agents that have emerged as a new therapeutic strategy for heart failure (HF) with reduced ejection fraction (HFrEF) and, potentially, for HF with preserved ejection fraction (HFpEF).
Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review
Zhen Ruan, Yixuan Jiang, Honghao Shi, Ruxu Jia, Carolina Oi Lam Ung & Hao Hu
doi : 10.1080/17512433.2023.2174099
The efficacy of once-weekly (O.W.) semaglutide for the treatment of type 2 diabetes mellitus (T2DM) has been demonstrated in clinical trials. The aim of this systematic literature review was to summarize real-world evidence for O.W. semaglutide.
